X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7422) 7422
Book Review (1094) 1094
Publication (651) 651
Newsletter (362) 362
Newspaper Article (174) 174
Magazine Article (49) 49
Book Chapter (34) 34
Conference Proceeding (31) 31
Government Document (8) 8
Dissertation (6) 6
Book / eBook (5) 5
Report (2) 2
Presentation (1) 1
Trade Publication Article (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (6348) 6348
tamoxifen (5176) 5176
humans (4946) 4946
female (4741) 4741
breast cancer (2852) 2852
oncology (2388) 2388
animals (2190) 2190
middle aged (2112) 2112
breast neoplasms - drug therapy (2065) 2065
tamoxifen - pharmacology (1724) 1724
tamoxifen - therapeutic use (1697) 1697
cancer (1619) 1619
aged (1518) 1518
adult (1496) 1496
postmenopausal women (1197) 1197
estrogen (1170) 1170
male (1145) 1145
research (1071) 1071
care and treatment (1028) 1028
breast neoplasms - pathology (982) 982
mice (980) 980
rats (845) 845
women (797) 797
health aspects (791) 791
antineoplastic agents, hormonal - therapeutic use (777) 777
therapy (760) 760
pharmacology & pharmacy (756) 756
tamoxifen - administration & dosage (740) 740
breast-cancer (725) 725
chemotherapy (711) 711
prevention (691) 691
analysis (648) 648
medicine & public health (641) 641
expression (619) 619
risk factors (607) 607
treatment outcome (598) 598
drug therapy (597) 597
tamoxifen - adverse effects (597) 597
breast neoplasms - metabolism (592) 592
abridged index medicus (551) 551
breast neoplasms - blood (533) 533
aged, 80 and over (514) 514
endocrinology & metabolism (501) 501
breast neoplasms - genetics (496) 496
article (480) 480
antineoplastic combined chemotherapy protocols - therapeutic use (462) 462
tamoxifen - analogs & derivatives (458) 458
estradiol - pharmacology (451) 451
prognosis (448) 448
estrogen antagonists - pharmacology (446) 446
biochemistry & molecular biology (443) 443
obstetrics & gynecology (442) 442
postmenopause (435) 435
receptors, estrogen - metabolism (431) 431
oncology, experimental (425) 425
aromatase inhibitors (423) 423
menopause (419) 419
apoptosis (417) 417
cell biology (413) 413
chemotherapy, adjuvant (412) 412
cells (411) 411
risk (398) 398
physiological aspects (395) 395
estradiol - blood (383) 383
cell line, tumor (382) 382
dose-response relationship, drug (382) 382
tumors (379) 379
estradiol (374) 374
time factors (374) 374
genetic aspects (366) 366
estrogen-receptor (351) 351
gene expression (351) 351
endocrine therapy (348) 348
antineoplastic agents - therapeutic use (342) 342
research article (328) 328
randomized-trial (327) 327
medicine (324) 324
antineoplastic agents, hormonal - adverse effects (322) 322
carcinoma (316) 316
breast neoplasms - prevention & control (310) 310
rats, sprague-dawley (295) 295
skin and connective tissue diseases (293) 293
proteins (291) 291
raloxifene (289) 289
antineoplastic agents, hormonal - pharmacology (288) 288
metastasis (284) 284
trial (283) 283
ovariectomy (281) 281
breast neoplasms - mortality (279) 279
rodents (279) 279
breast neoplasms - surgery (278) 278
disease-free survival (273) 273
anastrozole (270) 270
letrozole (269) 269
growth (265) 265
surgery (265) 265
aromatase inhibitors - therapeutic use (264) 264
clinical trials (264) 264
in-vitro (263) 263
estrogen antagonists - therapeutic use (262) 262
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (7906) 7906
Japanese (31) 31
German (27) 27
French (18) 18
Russian (15) 15
Polish (12) 12
Chinese (11) 11
Italian (6) 6
Spanish (6) 6
Portuguese (5) 5
Czech (3) 3
Dutch (3) 3
Korean (2) 2
Bulgarian (1) 1
Romanian (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Talanta, ISSN 0039-9140, 01/2015, Volume 132, pp. 775 - 784
Journal Article
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 02/2014, Volume 124, Issue 2, pp. 675 - 686
Journal Article
Journal Article
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, ISSN 1469-493X, 2018, Volume 11, Issue 11, pp. CD011094 - CD011094
Journal Article
Diabetes, ISSN 0012-1797, 11/2011, Volume 60, Issue 11, pp. 2872 - 2882
OBJECTIVE-To evaluate whether healthy or diabetic adult mice can tolerate an extreme loss of pancreatic a-cells and how this sudden massive depletion affects... 
INSULIN | HYPERGLUCAGONEMIA | ENDOCRINE PANCREAS | GLUCOSE-HOMEOSTASIS | ENDOCRINOLOGY & METABOLISM | RECEPTOR GENE | SECRETION | DIFFERENTIATION | HYPERPLASIA | ISLET CELLS | EXPRESSION | Insulin-Secreting Cells - secretion | Apoptosis - drug effects | Cell Count | Glucagon - genetics | Male | Diphtheria Toxin - toxicity | Insulin - blood | Glucagon - blood | Diabetes Mellitus, Experimental - blood | Hypoglycemia - prevention & control | Intercellular Signaling Peptides and Proteins - metabolism | Glucagon-Secreting Cells - drug effects | Insulin-Secreting Cells - metabolism | Hyperglycemia - chemically induced | Glucagon-Secreting Cells - metabolism | Diabetes Mellitus, Experimental - chemically induced | Diabetes Mellitus, Experimental - metabolism | Glucagon-Secreting Cells - secretion | Hyperglycemia - prevention & control | Promoter Regions, Genetic | Signal Transduction | Glucagon-Secreting Cells - pathology | Intercellular Signaling Peptides and Proteins - genetics | Pancreas - drug effects | Pancreas - pathology | Receptors, Glucagon - metabolism | Mice, Transgenic | Pancreas - metabolism | Heparin-binding EGF-like Growth Factor | Insulin - metabolism | Animals | Insulin-Secreting Cells - drug effects | Tamoxifen - pharmacology | Diabetes Mellitus, Experimental - pathology | Glucagon - metabolism | Mice | Streptozocin - toxicity | Insulin-Secreting Cells - pathology | Selective Estrogen Receptor Modulators - pharmacology | Index Medicus | Abridged Index Medicus | Islet Studies
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2009, Volume 27, Issue 23, pp. 3749 - 3756
Purpose Tamoxifen and fenretinide are active in reducing premenopausal breast cancer risk and work synergistically in preclinical models. The authors assessed... 
THERAPY | INHIBITION | N-(4-HYDROXYPHENYL) RETINAMIDE | CLINICAL-TRIAL | ONCOLOGY | BINDING PROTEIN-3 | AROMATASE | PHASE-I | EXPRESSION | SYNTHETIC RETINOID FENRETINIDE | GROWTH-FACTOR-I | Multivariate Analysis | Receptors, Estrogen - metabolism | Humans | Middle Aged | Insulin-Like Growth Factor Binding Protein 3 - blood | Receptor, ErbB-2 - metabolism | Premenopause - blood | Tamoxifen - administration & dosage | Incidence | Receptors, Progesterone - metabolism | Antineoplastic Agents, Hormonal - adverse effects | Selective Estrogen Receptor Modulators - therapeutic use | Anticarcinogenic Agents - administration & dosage | Antineoplastic Agents, Hormonal - therapeutic use | Carcinoma, Lobular - prevention & control | Fenretinide - administration & dosage | Adult | Female | Anticarcinogenic Agents - adverse effects | Breast Neoplasms - diagnostic imaging | Odds Ratio | Anticarcinogenic Agents - therapeutic use | Double-Blind Method | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Proportional Hazards Models | Tamoxifen - blood | Treatment Outcome | Mammography | Anticarcinogenic Agents - blood | Antineoplastic Agents, Hormonal - blood | Breast Neoplasms - prevention & control | Biomarkers, Tumor - blood | Drug Synergism | Fenretinide - blood | Fenretinide - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Tamoxifen - therapeutic use | Breast Neoplasms - blood | Tamoxifen - analogs & derivatives | Tamoxifen - adverse effects | Insulin-Like Growth Factor I - metabolism | Vitamin A - blood | Carcinoma, Intraductal, Noninfiltrating - prevention & control | Fenretinide - adverse effects | Index Medicus
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 07/2014, Volume 15, Issue 8, pp. 13333 - 13343
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 12/2003, Volume 95, Issue 23, pp. 1758 - 1764
Background: Tamoxifen, a selective estrogen receptor modulator (SERM), is converted to 4-hydroxy-tamoxifen and other active metabolites by cytochrome P450... 
PERFORMANCE LIQUID-CHROMATOGRAPHY | BREAST-CANCER | MAJOR METABOLITES | ONCOLOGY | 4-HYDROXYLATION | RANDOMIZED CONTROLLED-TRIAL | HUMAN LIVER-MICROSOMES | CYP2D6 ACTIVITY | HOT FLASHES | CYTOCHROME-P450 2D6 | VENLAFAXINE | Cytochrome P-450 CYP2D6 Inhibitors | Paroxetine - pharmacokinetics | Serotonin Uptake Inhibitors - pharmacokinetics | Prospective Studies | Cytochrome P-450 Enzyme Inhibitors | Selective Estrogen Receptor Modulators - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - blood | Cytochrome P-450 CYP3A | Humans | Microsomes, Liver - metabolism | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Tamoxifen - administration & dosage | Antineoplastic Agents, Hormonal - pharmacokinetics | Paroxetine - administration & dosage | Paroxetine - blood | Breast Neoplasms - enzymology | Adult | Female | Serotonin Uptake Inhibitors - blood | Chemotherapy, Adjuvant | Antineoplastic Agents, Hormonal - administration & dosage | Enzyme Inhibitors - pharmacology | Tamoxifen - blood | Selective Estrogen Receptor Modulators - administration & dosage | Treatment Outcome | Tamoxifen - pharmacokinetics | Breast Neoplasms - drug therapy | Antineoplastic Agents, Hormonal - blood | Selective Estrogen Receptor Modulators - blood | Serotonin Uptake Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - blood | Tamoxifen - analogs & derivatives | Aged | Paroxetine | Evaluation | Serotonin uptake inhibitors | Tamoxifen | Clinical trials | Plasma | Breast cancer | Drug therapy | Metabolism | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 11/2013, Volume 8, Issue 11, pp. e78670 - e78670
Retinol binding protein 4 (RBP4) is an adipokine that may contribute to the development of insulin resistance. However, how this adipokine is affected and its... 
WOMEN | METABOLIC SYNDROME | CHOLESTEROL | INSULIN-RESISTANCE | TAMOXIFEN | MULTIDISCIPLINARY SCIENCES | LOW-DENSITY-LIPOPROTEIN | VISCERAL ADIPOSITY | RETINOL-BINDING-PROTEIN-4 | CARDIOVASCULAR RISK | FENRETINIDE | Body Mass Index | Multivariate Analysis | Dyslipidemias - complications | Humans | Middle Aged | Insulin Resistance | Atherosclerosis - complications | Lipid Metabolism | Male | Cholesterol, VLDL - blood | Metabolic Syndrome - complications | Obesity, Morbid - complications | Atherosclerosis - blood | Metabolic Syndrome - blood | Diabetes Mellitus, Type 2 - blood | Dyslipidemias - blood | Triglycerides - blood | Cholesterol, HDL - blood | Adult | Cholesterol, LDL - blood | Female | Retinol-Binding Proteins, Plasma - metabolism | Diabetes Mellitus, Type 2 - complications | Obesity, Morbid - blood | Type 2 diabetes | Obesity | Low density lipoproteins | Analysis | Physiological aspects | Insulin resistance | Triglycerides | Retinoids | Binding proteins | Insulin | Protein binding | Lipoproteins (low density) | Particle size | Biomedical research | Anthropometry | Dyslipidemia | Lipids | Cardiovascular disease | Metabolic syndrome | Proteins | Body mass index | Vitamin A | Regression models | Atherosclerosis | Lipid metabolism | Diabetes mellitus (non-insulin dependent) | Lipoproteins (high density) | Medical research | Diabetes mellitus | Metabolic diseases | Inflammation | Breast cancer | Regression analysis | Metabolism | Patients | Low density lipoprotein | Lipoproteins (very low density) | Cholesterol | Medicine | Hospitals | Body mass | Womens health | Diabetes | Metabolic disorders | Endocrinology | Index Medicus
Journal Article